Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

MENLO PARK, Calif., May 23, 2013 /PRNewswire/ -- Virobay, Inc. today announced that their development of an oral treatment for pain has reached an important milestone, as Virobay has now initiated a Phase 1 clinical trial of VBY-036 - a selective cathepsin S inhibitor.  

The first Phase 1 trial of VBY-036 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of VBY-036 in healthy adults.

"The initiation of this Phase 1 trial with VBY-036 represents another significant development objective for Virobay," stated Robert Booth , Ph.D., Chief Executive Officer of Virobay.  "Published preclinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with a variety of painful disorders, including neuropathic pain.  In addition, research carried out by Virobay with selective cathepsin S inhibitors has demonstrated efficacy in preclinical models of both acute and chronic inflammatory pain and neuropathic pain," stated Robert Booth .  "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-036.  To the best of our knowledge, VBY-036 is first-in-class with this therapeutic approach for the treatment of pain."

"Reaching this important milestone brings us one step closer to providing a new treatment for patients suffering with painful conditions.  Virobay is committed to providing novel therapies for unmet medical needs and strives to constantly expand and improve treatment options for patients.  Virobay also initiated clinical studies with VBY-891, a selective cathepsin inhibitor in March of this year.  VBY-891 is being developed in partnership with LEO Pharma for the
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Village, Calif. (PRWEB) January 15, 2014 ... treatment and management through the genomic analysis of tumor ... offer Therapy Finder™, a web-based cancer decision support application ... reporting option with Cynvenio’s ClearID™ genomic test, Therapy Finder ...
(Date:1/15/2014)... Houston, TX (PRWEB) January 15, 2014 ... Alzheimer’s disease, and about 1 in 3 seniors will ... ( source ). These jaw-dropping figures have shocked many ... function and, hopefully, help prevent these tragic age-related cognitive ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... April 24, 2008 / b3c newswire / - ... are working on a project to synthesize a gene ... statistically expected and controlled ratio at preselected positions within ... core technology, Slonomics™, a unique DNA engineering platform using ...
... N.C. -- Duke University chemists have found a way ... thick in very large numbers, removing a major roadblock ... These single-walled carbon nanotubes also follow parallel paths as ... potentially impede electronic performance, said Duke associate chemistry professor ...
... Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) today announced ... results on Wednesday, April 30,2008, after the market closes. ... at 2:00 p.m. PT, which will be open to ... the company will review,the financial results and discuss other ...
Cached Biology Technology:Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library 2Nanotubes grown straight in large numbers 2Nanotubes grown straight in large numbers 3Sangamo BioSciences Announces First Quarter Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter Conference Call and Webcast 3
(Date:4/22/2014)... Analyzing thousands of breeding bird surveys sent in ... Canada over 35 years, wildlife researchers report that most ... northward or toward higher elevation in response to climate ... means that most previous studies of potential climate change ... or the other have likely underestimated the effects of ...
(Date:4/22/2014)... effects of temperature and precipitation on the global distribution ... of climate research, the UV-B radiation, is often neglected. ... colleagues from the Universities in Olomouc (Czechia), Halle and ... space agency in such a way that they can ... on organisms. , The basic input data were provided ...
(Date:4/22/2014)... your age" is another way of asking him or ... bring improvements. Certain cells of the immune system tend ... to illness. Because these cells are known to misbehave ... microgravity on immune cells to better understand how our ... the National Institute on Aging, part of the National ...
Breaking Biology News(10 mins):Wildlife response to climate change is likely underestimated, experts warn 2UV-radiation data to help ecological research 2For an immune cell, microgravity mimics aging 2For an immune cell, microgravity mimics aging 3For an immune cell, microgravity mimics aging 4For an immune cell, microgravity mimics aging 5
... , WEST LAFAYETTE, Ind. - Scientists could take greater ... of advanced techniques used to understand the mechanisms that ... former Purdue University researchers say. In a perspective ... Purdue assistant professor of genetics, and Ivan Baxter, a ...
... could make more tomatoes taste like heirlooms, reports an international ... scientist. The finding, which will be reported in the ... significant implications for the U.S. tomato industry, which annually harvests ... and fresh-market sales. "This information about the gene responsible ...
... big boss proteins that switch on broad developmental ... regulators of muscle development or fat metabolism. One ... protein, takes charge following a cellular crisis known ... by the accumulation of misfolded and aggregated proteins. ...
Cached Biology News:Adoption of advanced techniques could propel crop improvement 2Discovery may lead to new tomato varieties with vintage flavor and quality 2Forty's a crowd 2Forty's a crowd 3Forty's a crowd 4
Immunochemistry 1 & 2...
...
Hucal Agx Antigen Expression Service Specificity: Hucal Agx ...
MHC. Sections include: the isolation and functional properties of antigen-presenting cells analysis of MHC class II endocytosis and peptide turnover analysis of signalling via MHC class II molecu...
Biology Products: